From insightful talks to a young professionals summit, here's what not to miss and how to register. Photo via Getty Images

Editor's note: The tech event scene is heating up in August. From insightful talks to a young professionals summit, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Aug. 5 – Tech and Tequila Talk

Hear from guest speaker David Cohen, founder & CEO of Dallas-based Superposition, at the latest installment of Tech and Tequila Talk. The event will focus on breaking down ambiguity in data and AI projects through collaborative workshops.

This event takes place Tuesday, Aug. 5, from 5-7 p.m. at the Ion. Click here to register.

Aug. 11-16 – Black is Tech Week

Black is Tech Week will bring events for tech professionals, entrepreneurs and students to Houston through summits, career fairs, networking events and more. The event will feature speakers from Amazon, Microsoft, Google and many other companies.

This event begins Monday, Aug. 1. Find more information here.

Aug. 12 – NASA Stories at the Ion

Head to the Ion for the new morning series spotlighting the human side of space exploration. Each session will feature personal and powerful stories from astronauts and key NASA personnel. Anthony Vareha, NASA Flight Director and Flight Operations Directorate, whose primary duty is the safe operation of the International Space Station will speak this month.

This event begins Tuesday, Aug. 12, from 8:30-10 a.m. Find more information here.

Aug. 14 – Pickle Lab’s One-Year Anniversary Celebration

Enjoy an afternoon of open-play pickleball, beats by a live DJ, raffle giveaways and free swag at the first anniversary celebration of Pickle Lab in the Ion District. WonderPops will provide complimentary pops while supplies last, and Second Draught will serve each guest a free beverage.

This event takes place Thursday, Aug. 14, from 4-7 p.m. RSVP here.

Aug 19 – Navigating the Economy: Insights from Darren King

Darren King, chief investment officer of Moody Bank, will share his expert insights on the state of the economy and its impact on Houston’s future. Gain a deeper understanding of market trends, economic shifts and what they mean for businesses and individuals in the city.

This event takes place Tuesday, Aug. 19, from 11:30-1 p.m. RSVP here.

Aug. 21 – Transition on Tap

Greentown Labs’ signature networking event returns in August to foster conversations and connections within Houston's climate and energy transition ecosystem. Entrepreneurs, investors, students, philanthropists and more are invited to attend, meet colleagues, discuss solutions and engage with the growing community.

This event takes place Thursday, Aug. 21, at 5:30 p.m. at Greentown Labs. Click here to register.

Aug. 22 – Determined to Lead Women Lunch: Investing Through Market Cycles with Ellen Wilkirson

EnergyTech Nexus hosts a monthly Determined to Lead Women’s Lunch as part of its ongoing efforts to create safe spaces for women leaders in the energy transition to connect, learn and lead. The August session features Ellen Wilkirson, principal at Rev Innovations. With deep experience across traditional and transition energy sectors, Wilkirson will share how she’s approached investing through multiple market and commodity cycles and what it means to be a clean energy investor in today’s evolving landscape.

This event takes place Friday, Aug. 22, at 1 p.m. Click here to register.

Aug. 26 – Software Day at the Ion: Positioning your Startup to Capitalize on Market Trends

Software Day is a monthly series driving the support, inspiration and connections needed to help startups on their path to rapid, sustainable growth. Each month, Software Day will include office hours (by application), a keynote session and networking. This month’s panel discussion will feature Remington Tonar, co-founder of Cart.com, and Josh Teekell, founder of SmartAC.com.

This event takes place Tuesday, Aug. 26, from 3:30-7 p.m. Click here to register.

Aug. 27 – Future of Flight: Inside Venus Aerospace with Founder Sassie Duggleby

Join EO Houston for an exclusive, behind-the-scenes conversation with Sassie Duggleby, co-founder and CEO of Venus Aerospace, a Houston-based company pioneering breakthrough propulsion systems for hypersonic and space applications.

This event takes place Wednesday, Aug. 27, at 10 a.m. at Venus Aerospace. It is open to EO members and partners only. Click here to register.

Aug. 27 – The Future of American Science: A Conversation With US Rep. Brian Babin

U.S. Rep. Dr. Brian Babin and Paul Cherukuri, vice president of innovation at Rice University, will discuss how the United States remains at the forefront of space exploration, emerging technologies and scientific advancement, as well as what's next and what's at stake for the future of science policy.

This event takes place Wednesday, Aug. 27, from 3-4 p.m. at James A. Baker III Hall on Rice University's campus. Click here to register.

Aug. 28 – HYPE Summit

The third annual Houston Young Professionals and Entrepreneurs (HYPE) Summit is a day-long conference featuring panel discussions with business and thought leaders, workshop-style breakout sessions and networking opportunities. This year's event—under the theme Step Into the Spotlight—will feature speakers from First Bight Ventures, Bot Auto, Regions Bank, Lopez Negrete Communications and Umbrage.

This event takes place Thursday, Aug. 28, from 8:30 a.m.-5:30 p.m. at The Hobby Center for the Performing Arts. Click here to register.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”